Business, energy, technology, markets and global industry news from Business News Today

immunotherapy

PharmaDeviceNews immunotherapy
Representative image: Antengene’s ATG-106 licensing deal highlights growing biotech interest in CDH6 x CD3 T cell engagers for solid tumor immunotherapy.
Pharma & Biotech

Antengene, K2 Therapeutics deal signals fresh momentum for solid tumor TCEs

Find out how Antengene’s ATG-106 licensing deal could shape the next phase of solid tumor T cell engager development.

Read More
Representative image: Laboratory research on macrophage-targeted therapies highlights 101 Therapeutics’ push for independent review of 101-PGC-005 in Bundibugyo Ebola disease.
Pharma & Biotech

Can 101 Therapeutics’ macrophage-targeting approach change the race for a Bundibugyo Ebola treatment?

101 Therapeutics has released new data on 101-PGC-005 for Bundibugyo Ebola disease. Discover what it could mean for outbreak response and drug development.

Read More
Representative image: An oncologist discusses colon cancer treatment options with a patient, reflecting Genentech’s Tecentriq Priority Review and the growing role of immunotherapy in stage III dMMR/MSI-H colon cancer care.
Pharma & Biotech

Why Genentech’s Tecentriq Priority Review could change adjuvant colon cancer treatment

Find out how Genentech’s Tecentriq Priority Review could reshape adjuvant treatment for stage III dMMR/MSI-H colon cancer.

Read More
Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.
Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.

Read More
Pharma & Biotech

AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer

Imfinzi has FDA approval with BCG in early high-risk bladder cancer. The next test is adoption, recurrence data and real-world use.

Read More
Representative image of researchers working in a modern cell therapy laboratory, reflecting T-CURX’s acquisition of Pantherna Therapeutics and the growing race to advance in vivo CAR-T, mRNA delivery and lipid nanoparticle technologies.
Pharma & Biotech

Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing

T-CURX and Pantherna are combining CAR-T, mRNA and LNP platforms. Europe’s in vivo cell therapy race just became more serious.

Read More
Representative image of an oncologist reviewing lung cancer scans in a modern treatment room, reflecting Amgen’s European approval for Imdylltra and the growing shift toward bispecific antibody therapies for extensive-stage small cell lung cancer.
Pharma & Biotech

Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?

Amgen’s Imdylltra has European approval in relapsed small cell lung cancer. Survival data now face reimbursement and adoption tests.

Read More
Representative image of a cancer care specialist reviewing gastroesophageal scan data as BeOne Medicines’ HER2-positive gastroesophageal cancer results draw attention after ASCO 2026.
Pharma & Biotech

Could BeOne’s zanidatamab regimen reset expectations in HER2-positive gastroesophageal cancer?

Find out how BeOne’s HERIZON-GEA data could reshape HER2-positive gastroesophageal cancer treatment after ASCO 2026.

Read More
Pharma & Biotech

Can Brenus Pharma crack the cold-tumor problem in metastatic colorectal cancer?

Find out how Brenus Pharma’s STC-1010 FDA IND acceptance could reshape MSS colorectal cancer immunotherapy development.

Read More
Pharma & Biotech

Why AstraZeneca’s EMERALD-3 and SERENA-6 data could influence future standards of cancer care

Could AstraZeneca’s latest ASCO 2026 cancer data reshape future treatment sequencing in liver and breast oncology? Read the full analysis.

Read More